Uganda's Inspectorate of Government Suspends NDA Board Appointments

The Inspectorate of Government (IGG) in Uganda recently intervened to halt the inauguration of the newly appointed National Drug Authority (NDA) board members, citing significant procedural irregularities and potential conflicts of interest. This development, which occurred in March 2026, underscores the stringent legal and administrative requirements governing appointments to statutory bodies. The IGG's directive highlighted concerns over the lack of proper consultation with nominating bodies, absence of Cabinet approval, failure to obtain a certificate of financial implication, and incomplete security vetting. Furthermore, questions were raised regarding the tenure of some reappointed members and alleged conflicts of interest, prompting a broader examination of governance within the NDA and adherence to the National Drug Policy and Authority Act (Cap 206).

The governance of statutory bodies is a cornerstone of effective public administration, demanding strict adherence to established legal frameworks and transparent appointment processes. In a significant development for Uganda's regulatory landscape, the Inspectorate of Government (IGG) recently intervened to suspend the inauguration of the National Drug Authority (NDA) board, scheduled for March 2026. This intervention, predicated on allegations of procedural non-compliance and conflicts of interest, has cast a spotlight on the meticulous legal requirements for constituting such critical oversight bodies.

The National Drug Authority plays a pivotal role in safeguarding public health by regulating the manufacture, importation, distribution, and quality of drugs in Uganda. The integrity and legitimacy of its governing board are therefore paramount to its effective functioning and public trust. The IGG's decisive action serves as a potent reminder to all public entities and legal practitioners of the imperative to uphold administrative law principles and statutory mandates in all aspects of public appointments. This article will delve into the legal context surrounding the NDA board appointments, analyze the grounds for the IGG's intervention, and discuss the broader implications for governance and legal compliance in Uganda.

The National Drug Authority (NDA) was established by the National Drug Policy and Authority Statute of 1993, which was subsequently revised and became the National Drug Policy and Authority Act, Cap. 206 of the Laws of Uganda. This foundational legislation mandates the NDA to ensure the availability of essential, efficacious, and cost-effective drugs to the Ugandan population, regulate the import, export, and sale of pharmaceuticals, control drug quality, and promote local drug production, among other functions.

The Act outlines the composition of the Authority, typically comprising around 17 to 20 members drawn from various government ministries, professional bodies, and public representatives. These members are generally appointed for a renewable term, often specified as four years. The proper constitution of this board is crucial for the NDA to effectively execute its mandate, as the board provides strategic direction and oversight. Historically, changes in the NDA board have sometimes been accompanied by controversy, such as the dissolution of a board in 2011 due to disagreements over recruitment, leading to an interim board. Furthermore, legal challenges have arisen concerning the appointment of key officials, as seen in 2017 when the High Court nullified the appointment of an Executive Director on grounds that the position, as filled, was non-existent under the Act.

The recent intervention by the Inspectorate of Government (IGG) concerning the 9th NDA board appointments highlights critical issues in public sector governance. On March 2, 2026, the Deputy IGG, Anne Twinomugisha Muhairwe, directed the NDA secretary to halt the appointment of Dr. Medard Bitekyerezo and Dr. Muhammad Mbabali, pending investigations into alleged irregularities. The IGG's directive was based on a whistleblower’s petition detailing several breaches of established procedures. These included the alleged absence of mandatory consultations with respective professional bodies, lack of Cabinet approval for the appointments, and the failure to secure a certificate of financial implication from the Ministry of Finance. Additionally, concerns were raised about the omission of mandatory security vetting by Interpol, a crucial step to authenticate reappointments.

A significant point of contention revolved around the tenure of the reappointed members. The whistleblower claimed that Dr. Bitekyerezo and Dr. Mbabali had already served for nine years, completing three terms, despite the National Drug Policy and Authority Act being silent on the maximum number of terms a member may serve. While the Act does not explicitly limit terms, the IGG's investigation into this aspect suggests a scrutiny of the spirit of good governance and the potential for entrenchment. Furthermore, allegations of conflicts of interest were central to the IGG's concerns. For instance, it was noted that Dr. Bitekyerezo also served on the board of the National Medical Stores (NMS), while the NMS General Manager sat on the NDA board, creating a supervisory conflict given the NDA's role in quality assurance over NMS products.

The IGG's actions are legally underpinned by the Inspectorate of Government Act, Cap 32, which empowers the Inspectorate to investigate and prevent corruption, abuse of authority, and public maladministration. Disobedience of lawful orders issued by the Inspectorate is an offense under Section 34(C) of this Act, carrying a potential sentence of up to three years imprisonment upon conviction. This underscores the serious legal ramifications of disregarding the IGG's directives. The incident reflects a broader challenge in public appointments where procedural safeguards, designed to ensure transparency, meritocracy, and accountability, are sometimes overlooked. The IGG's intervention serves as a vital check on executive power and reinforces the importance of administrative due process in maintaining the integrity of regulatory bodies.

The IGG's halt of the NDA board inauguration serves as a critical reminder for legal practitioners and public officials alike regarding the stringent requirements for appointments to statutory bodies in Uganda. It underscores that adherence to procedural fairness, transparency, and the avoidance of conflicts of interest are not mere formalities but fundamental pillars of good governance. The ongoing investigations into the alleged irregularities, including the lack of proper consultations, Cabinet approval, financial certification, and security vetting, highlight the robust oversight role played by institutions like the IGG in upholding the rule of law.

Practitioners advising public bodies must ensure meticulous compliance with the National Drug Policy and Authority Act, Cap 206, and other relevant administrative laws governing appointments. This includes diligent verification of all procedural steps, from nominations and security clearances to ministerial and Cabinet approvals. The outcome of the IGG's investigations will be keenly watched, as it may lead to further clarifications on board tenure limits, conflict of interest guidelines, and potentially influence future legislative amendments to strengthen the appointment processes for statutory bodies across Uganda. This incident reinforces the need for continuous vigilance in public sector appointments to safeguard institutional integrity and public trust.